New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|27|4357-4378

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.27, 2014-01, pp. : 4357-4378

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis

By  

Current Pharmaceutical Biotechnology, Vol. 3, Iss. 3, 2002-01 ,pp. : 197-225

Bentham Science Publishers

Access to resources Recommend Favorite

The Methylerythritol Phosphate (MEP) Pathway for Isoprenoid Biosynthesis as a Target for the Development of New Drugs Against Tuberculosis

By  

Current Medicinal Chemistry, Vol. 18, Iss. 9, 2011-03 ,pp. : 1325-1338

Bentham Science Publishers

Access to resources Recommend Favorite

Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis - An Update

By  

Medicinal Chemistry Reviews - Online, Vol. 2, Iss. 5, 2005-10 ,pp. : 393-413

Bentham Science Publishers

Access to resources Recommend Favorite

New tuberculosis drug development: targeting the shikimate pathway

By Kapnick Senta M   Zhang Ying  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 5, 2008-05 ,pp. : 565-577

Informa Healthcare

Access to resources Recommend Favorite

Mycolic acids for the control of tuberculosis

By Sekanka Gianna   Baird Mark   innikin David   Grooten Johan  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 3, 2007-03 ,pp. : 315-331

Informa Healthcare

Access to resources Recommend Favorite